Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of insulin glulisine compared with insulin lispro in children and adolescents with type 1 diabetes mellitus: a 26 week, multicenter, open, parallel clinical trial

X
Trial Profile

Efficacy and safety of insulin glulisine compared with insulin lispro in children and adolescents with type 1 diabetes mellitus: a 26 week, multicenter, open, parallel clinical trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glulisine (Primary) ; Insulin; Insulin glargine; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 29 Oct 2008 Insulin glulisine has been approved for the use in Children 4 years and older based on results from this study.
    • 11 Sep 2008 Results presented at EASD
    • 19 Jan 2007 Status changed from recruting

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top